We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
Read MoreHide Full Article
Glaukos Corporation (GKOS - Free Report) reported an adjusted loss per share of 45 cents for the third quarter of 2022, beating the Zacks Consensus Estimate of a loss of 53 cents by 15.1%. However, the third-quarter loss was wider than the adjusted loss of 31 cents reported in the year-ago quarter.
GAAP loss per share for the quarter was 58 cents against earnings of 13 cents per share in the year-ago period. Please note that the prior-year period included a $30 million payment receipt related to the company’s settlement of patent litigation with Ivantis.
Revenues in Detail
Glaukos registered revenues of $71.3 million in the third quarter, down 4.6% year over year on a reported basis and 1.6% at constant currency (cc). The figure, however, surpassed the Zacks Consensus Estimate by 5%.
Quarter in Details
In the quarter under review, Glaukos recorded Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million.
Margin Trend
In the quarter under review, Glaukos’ gross profit declined 8.6% to $54.4 million. Gross margin contracted approximately 300 basis points (bps) to 76%.
Selling, general and administrative expenses rose 6% to $47.1 million. Research and development expenses were almost flat year over year at $28.9 million. Total operating expenses of $70.8 million increased 12.2% year over year.
Glaukos Corporation Price, Consensus and EPS Surprise
Operating loss in the reported quarter totaled $21.6 million compared with a total operating loss of $11 million in the year-ago quarter.
Financial Update
Glaukos exited third-quarter 2022 with cash and cash equivalents and short-term investments of $371 million compared with $391.2 million at the end of the first quarter.
2022 Guidance
Glaukos raised the lower range of its revenue guidance for the full year based on solid execution globally and better-than-expected revenues.
For 2022, Glaukos now expects net sales between $278 million and $280 million, compared with the previous projection of net sales between $270 million and $280 million. The Zacks Consensus Estimate for the same stands at $278.41 million.
Our Take
Glaukos exited the third quarter of 2022 with robust results, wherein earnings and revenues beat estimates.
It launched iPrime — a new disco elastic delivery device — in the latter part of the second quarter. In the latter part of the first quarter, the company had launched the iAccess device for go anatomy procedures. The addition of these new devices will provide unique solutions designed to grow and improve treatment options for surgeons, customers and patients. The company’s iAccess device received positive market feedback.
In August, Glaukos announced that it had received the FDA 510(K) clearance for iStent infinite — the first FDA-cleared micro-invasive implantable device used as a standalone treatment option for glaucoma patients to reduce elevated intraocular pressure. The potential launch of the product, expected later this year, will likely accelerate Glaucoma net sales growth going forward. The company is also developing several other treatment options in its pipeline. These developments raise our optimism about the stock.
However, wider adjusted loss per share and lower overall revenues on a year-over-year basis are disappointing. Glaukos incurred an operating loss in the reported quarter, raising our apprehension. The company’s operation in a stiff competitive space is also worrying.
Zacks Rank and Key Picks
Currently, Glaukos carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. (ELV - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
Elevance Health, carrying a Zacks Rank #2 (Buy), reported third-quarter 2022 adjusted EPS of $7.53, which beat the Zacks Consensus Estimate by 6.1%. Revenues of $39.63 billion outpaced the consensus mark by 1.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Elevance Health has an earnings yield of 5.5% against the industry’s (2.3%). ELV’s earnings surpassed estimates in all the trailing four quarters, the average being 4.1%.
Medpace Holdings, having a Zacks Rank #1, reported third-quarter 2022 adjusted EPS of $2.05, which beat the Zacks Consensus Estimate by 39.5%. Revenues of $384 million outpaced the consensus mark by 8.1%.
Medpace Holdings has an estimated growth rate of 22.7% for 2022. MEDP’s earnings surpassed estimates in the trailing four quarters, the average being 22.04%.
Merit Medical, flaunting a Zacks Rank #1, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
Glaukos Corporation (GKOS - Free Report) reported an adjusted loss per share of 45 cents for the third quarter of 2022, beating the Zacks Consensus Estimate of a loss of 53 cents by 15.1%. However, the third-quarter loss was wider than the adjusted loss of 31 cents reported in the year-ago quarter.
GAAP loss per share for the quarter was 58 cents against earnings of 13 cents per share in the year-ago period. Please note that the prior-year period included a $30 million payment receipt related to the company’s settlement of patent litigation with Ivantis.
Revenues in Detail
Glaukos registered revenues of $71.3 million in the third quarter, down 4.6% year over year on a reported basis and 1.6% at constant currency (cc). The figure, however, surpassed the Zacks Consensus Estimate by 5%.
Quarter in Details
In the quarter under review, Glaukos recorded Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million.
Margin Trend
In the quarter under review, Glaukos’ gross profit declined 8.6% to $54.4 million. Gross margin contracted approximately 300 basis points (bps) to 76%.
Selling, general and administrative expenses rose 6% to $47.1 million. Research and development expenses were almost flat year over year at $28.9 million. Total operating expenses of $70.8 million increased 12.2% year over year.
Glaukos Corporation Price, Consensus and EPS Surprise
Glaukos Corporation price-consensus-eps-surprise-chart | Glaukos Corporation Quote
Operating loss in the reported quarter totaled $21.6 million compared with a total operating loss of $11 million in the year-ago quarter.
Financial Update
Glaukos exited third-quarter 2022 with cash and cash equivalents and short-term investments of $371 million compared with $391.2 million at the end of the first quarter.
2022 Guidance
Glaukos raised the lower range of its revenue guidance for the full year based on solid execution globally and better-than-expected revenues.
For 2022, Glaukos now expects net sales between $278 million and $280 million, compared with the previous projection of net sales between $270 million and $280 million. The Zacks Consensus Estimate for the same stands at $278.41 million.
Our Take
Glaukos exited the third quarter of 2022 with robust results, wherein earnings and revenues beat estimates.
It launched iPrime — a new disco elastic delivery device — in the latter part of the second quarter. In the latter part of the first quarter, the company had launched the iAccess device for go anatomy procedures. The addition of these new devices will provide unique solutions designed to grow and improve treatment options for surgeons, customers and patients. The company’s iAccess device received positive market feedback.
In August, Glaukos announced that it had received the FDA 510(K) clearance for iStent infinite — the first FDA-cleared micro-invasive implantable device used as a standalone treatment option for glaucoma patients to reduce elevated intraocular pressure. The potential launch of the product, expected later this year, will likely accelerate Glaucoma net sales growth going forward. The company is also developing several other treatment options in its pipeline. These developments raise our optimism about the stock.
However, wider adjusted loss per share and lower overall revenues on a year-over-year basis are disappointing. Glaukos incurred an operating loss in the reported quarter, raising our apprehension. The company’s operation in a stiff competitive space is also worrying.
Zacks Rank and Key Picks
Currently, Glaukos carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Elevance Health, Inc. (ELV - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
Elevance Health, carrying a Zacks Rank #2 (Buy), reported third-quarter 2022 adjusted EPS of $7.53, which beat the Zacks Consensus Estimate by 6.1%. Revenues of $39.63 billion outpaced the consensus mark by 1.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Elevance Health has an earnings yield of 5.5% against the industry’s (2.3%). ELV’s earnings surpassed estimates in all the trailing four quarters, the average being 4.1%.
Medpace Holdings, having a Zacks Rank #1, reported third-quarter 2022 adjusted EPS of $2.05, which beat the Zacks Consensus Estimate by 39.5%. Revenues of $384 million outpaced the consensus mark by 8.1%.
Medpace Holdings has an estimated growth rate of 22.7% for 2022. MEDP’s earnings surpassed estimates in the trailing four quarters, the average being 22.04%.
Merit Medical, flaunting a Zacks Rank #1, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.